Scott Rocklage, PhD, is a Managing Partner at 5AM Ventures. This company is a venture capital firm with a focus on advanced life science technologies in the fields of medical technology, research instruments, and biopharmaceuticals. With his extensive medical background, Dr. Rocklage is heavily involved in researching the medical advances and drugs potential at firms that 5AM Ventures is interested in investing in.
Dr. Rocklage graduated from the University of California, Berkley with a degree in Chemistry. He earned his Ph.D. in Chemistry at the Massachusetts Institute of Technology. Before joining 5AM Ventures he had a long career in healthcare management and research within the field of medicine. He held a number of research and development positions at Salutar and Catalytica. He has also held a number of executive-level positions including the President, Chairman, and Chief Executive of Nycomed Interventional. He was also the CEO and President of Nycomed Salutar and the Chairman and CEO of Cubist Pharmaceuticals.
During his career Dr. Scott Rocklage has led six drug candidates into clinical trials. He has successfully had three drugs approved by the Federal Drug Administration; Cubicin, Teslascan, and Omniscan. He has written more than 100 scientific papers that have been published in peer-reviewed publications and holds over 30 patents for inventions he has either invented or co-invented.
Dr. Rocklage sits on a number of Boards for pharmaceutical companies. Among these he is the Chairman of the Board of Relypsa, Achaogen, and Semprus. He also serves on the Boards for Pulmatrix, Variation, and WaveRx.